Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US

2Firsts Events by 2FIRSTS, edited by Sophia Lv
Aug.19.2024
Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
Accorto CEO Tom Beaudet and CSO Dr. Vince Angelico visit 2FIRSTS HQ for in-depth discussion on US e-cigarette industry.

On August 19, Tom Beaudet, CEO of the U.S. compliance company Accorto, and Dr. Vince Angelico, CSO (Chief Scientific Officer), visited the headquarters of 2FIRSTS to have a detailed discussion with Alan Zhao, co-founder and CEO of 2FIRSTS. Both sides explored the high-quality development of the e-cigarette industry in the American market.

 

Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
Tom (third from the right), Vincent (fourth from the right), Alan Zhao (second from the right), and 2FIRSTS staff members posing for a photo. | Image source: 2FIRSTS

 

During the meeting, Alan Zhao warmly welcomed the arrival of the Accorto delegation and expressed appreciation for their professional insights in the field of PMTA compliance. Alan Zhao stated that with the U.S. Food and Drug Administration (FDA) continuously strengthening its regulation and enforcement of the e-cigarette market, compliance in the e-cigarette industry has become a crucial issue that companies cannot afford to overlook. In the face of market changes, companies must pay close attention to compliance services in order to ensure their sustainable and steady development.

 

Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
2024 Global New Tobacco Regulations Report" produced by 2FIRSTS|Image source: 2FIRSTS

 

In order to deepen mutual understanding and cooperation, Alan Zhao on behalf of 2FIRSTS presented Tom with the "2024 Global New Tobacco Regulation Report" (English version) produced by 2FIRSTS. The report provides a comprehensive analysis of the current global regulation of novel tobacco products and their development trends, offering valuable insights and guidance to the industry.

 

Tom highly praised 2FIRSTS' professionalism and contribution to the industry's development, and stated that he looks forward to deeper collaboration with 2FIRSTS in the e-cigarette compliance field in the future. Accorto, as a leading provider of PMTA compliance services, has been dedicated to assisting e-cigarette companies in FDA reviews to ensure products can legally enter the US market.

 

This exchange not only deepened mutual understanding between both parties, but also laid a solid foundation for future cooperation. 2FIRSTS and Accorto have both expressed their commitment to working together to promote the healthy and orderly development of the e-cigarette industry, providing global consumers with safer and more compliant e-cigarette products.

 

As a key media and research institution in the e-cigarette industry, 2FIRSTS will continue to leverage its influence within the industry to promote information exchange and knowledge sharing. We will work with partners like Accorto to contribute to the high-quality development of the e-cigarette industry.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
The Global State of Tobacco Harm Reduction, a project operated by Knowledge·Action·Change, estimates that about 200 million people worldwide use non-combustible nicotine products including vapes, heated tobacco, nicotine pouches and snus. Its 2026 report says use of these products rose alongside declining smoking rates in 28 countries it analyzed. The data do not establish that all 200 million users have quit smoking, nor do they prove a direct causal relationship. GSTHR also says regulatory restrictions on the products continue to expand in many markets.
Sep.10
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
A 12-week European Commission consultation on revising the Tobacco Products Directive and Tobacco Advertising Directive is due to close on Aug. 14, 2026. The Commission has identified e-cigarette flavours, disposable vapes, tobacco heating devices, nicotine pouches, nicotine-free e-cigarettes, packaging and digital marketing among areas for possible new EU rules. National regulations already vary significantly across the bloc, a fragmentation the Commission says creates internal-market barriers and distorts competition. No formal revised TPD/TAD legislative text has yet been published, with the Commission currently indicating December 2026 for the legislative initiative.
Aug.14
Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
A new Swedish study found oral mucosal lesions in 79% of examined nicotine pouch users and 89% of tobacco-derived snus users, with different tissue-response patterns between the two categories. For manufacturers and regulators, the findings shift attention toward product formulation, flavouring, pouch materials and local oral exposure, not only whether a product contains tobacco. The study found no higher prevalence of caries or periodontal disease, but it could not establish causality, long-term outcomes or differences between individual products or designs.
Special Report
Jul.27
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24